Treatment plans optimized for intensity modulated proton therapy (IMPT) may be sensitive to range variations. The dose distribution may deteriorate substantially when the actual range of a pencil beam does not match the assumed range. We present two treatment planning concepts for IMPT which incorporate range uncertainties into the optimization. The first method is a probabilistic approach. The range of a pencil beam is assumed to be a random variable, which makes the delivered dose and the value of the objective function a random variable too. We then propose to optimize the expectation value of the objective function. The second approach is a robust formulation that applies methods developed in the field of robust linear programming. This approach optimizes the worst case dose distribution that may occur, assuming that the ranges of the pencil beams may vary within some interval. Both methods yield treatment plans that are considerably less sensitive to range variations compared to conventional treatment plans optimized without accounting for range uncertainties. In addition, both approaches-although conceptually different-yield very similar results on a qualitative level.
Introduction
In recent years, intensity modulated proton therapy (IMPT) has evolved into a central issue in radiotherapy research. Using a scanning proton beam, highly conformal dose distributions can be delivered to a target of complex shape. Different inverse planning approaches have been proposed in order to optimize treatment plans for IMPT (Lomax 1999) .
The accuracy of IMPT is potentially compromised by uncertainties concerning the range of a proton beam in the patient. Uncertainties in the range may originate from artefacts in the CT image or the conversion of Hounsfield units to stopping powers. Another source of range variations is delivery uncertainties and changes in the patient's geometry 3 . Currently, heuristics are applied in order to account for potential range uncertainties in treatment planning for proton radiotherapy. These methods may e.g. aim at avoiding Bragg peaks that stop directly in front of an organ at risk, so that the dose burden of the critical structure would dramatically increase if the real proton range was larger than the assumed range. Examples are the patchfield technique applied in conjunction with passive scattering devices (Bussiere and Adams 2003) , or the beam arrangement described by Lomax et al (2001) for scanning beam delivery.
Positron emission tomography (PET) measurements during or directly after treatment represent a method to assess range uncertainties experimentally (Parodi et al 2002, Parodi and . By nuclear interactions, the proton beam generates the β + -emitters 10 C, 11 C and 15 O in the patient. The measured activity distribution in the patient can be compared to the expected activity distribution, which in turn may detect a deviation of the real proton range compared to the assumed range.
In this paper, we demonstrate that IMPT treatment plans may be sensitive to changes in the proton range. A treatment plan may exhibit an almost homogeneous dose distribution across the tumour if the actual proton range matches the range that was assumed in the optimization. However, changes in the proton range may cause hot and cold spots in the tumour and unexpected high doses to adjacent organs at risk.
Next, we present two concepts to incorporate range uncertainties into IMPT optimization that make treatment plans less sensitive to range uncertainties. That is, we aim at improving the dose distribution that results if the actual range is shorter or larger than the assumed range. Both concepts are derived from methods which have been investigated in order to incorporate organ movements into the optimization of intensity modulated radiation therapy (IMRT) for photons.
The first approach is a probabilistic method. Following this approach, the range of a proton beam is considered a random variable. Consequently, the delivered dose and the value of the objective function become random variables as well. The proposed treatment planning approach consists of optimizing the expected value of the objective function. This method has been investigated in the context of organ movement by Unkelbach and Oelfke (2004, 2005) , Unkelbach (2006) and Löf et al (1995 Löf et al ( , 1998 .
The second approach is based on a robust formulation of the IMPT optimization problem. We use methods developed in the field of robust optimization in operations research in order to obtain treatment plans that are protected against uncertainties due to range variations. The approach effectively optimizes the worst case that may occur, assuming that the range may vary within some interval. This approach has been investigated in the context of handling respiratory motion in IMRT optimization by Chan et al (2006) .
Both concepts are applied to an idealized two-dimensional geometry in order to demonstrate their potential. The quantification of range uncertainties, which are needed as input, is not a topic of the paper. We focus solely on range variations ignoring other potential sources of uncertainty. Range uncertainties are modelled in an abstract manner, i.e. we assume uncertainty in the proton range without modelling an underlying cause of the range variation 4 . It is our ambition to provide an IMPT planning concept which is based on the optimization of a meaningful objective, so that the method can be expected to work independently of tumour site and other irradiation parameters. The amount of improvement that the method potentially yields will of course depend on the tumour site. The remaining part of the paper is organized as follows: in section 2 we introduce the phantom geometry that is used in the paper along with the objective functions of the two approaches. In section 3, we demonstrate that IMPT treatment plans that are optimized without taking range uncertainties into account, may deteriorate substantially when the range of the proton beam changes. Sections 4 and 5 define the probabilistic and the robust optimization concepts, respectively. These two sections are widely independent, i.e. the robust formulation can be understood without going through the probabilistic approach and vice versa. Section 6 demonstrates treatment planning results for both approaches. The results are summarized in section 7 and the supplement in section 8 shows treatment planning results for another beam geometry, that is the patch-field geometry.
Preliminaries

The geometry of the phantom
We consider the RTOG benchmark phantom geometry: we consider a two-dimensional slice of a circular patient of radius 10 cm. A circular organ at risk (OAR) of radius 1.5 cm is located in the centre of the patient. The OAR is surrounded by a horse shoe shaped tumour of inner radius 1.8 cm and outer radius 4.0 cm (figure 1). We consider two beam geometries: all sections except section 8 consider three beams at 315 • , 0 • and 45 • . Section 8 considers two beams at 135 • and 225 • . For dose calculation and dose delivery, we assume pristine Bragg peaks. For each beam, Bragg peaks are placed on a regular, rectangular grid, which is in line with the proton beam. Spots are placed in a region which encompasses the tumour plus a 1 cm isotropic margin around the tumour. The spacing of the spots is 4 mm in both the axial and the lateral direction. A Bragg peak for a given lateral position and a given depth is referred to as a beamlet and is assigned a fluence weight during the optimization. Hence, this implementation corresponds to 3D IMPT optimization (in contrast to distal edge tracking (DET) or the 2.5D technique) using the classification introduced in Lomax (1999) . For the dose calculation, we use a pencil beam algorithm and assume an initial width of 5 mm standard deviation of the Gaussian pencil beam at the entrance point. The phantom is assumed to be homogeneous and water equivalent.
The dose calculation accurately models the lateral and distal fall-off of the pencil beam which is presumably the most relevant feature in the context of this work. Range variations of a pencil beam are modelled by changing the proton energy, which approximately corresponds to a shift of dose distribution of the pencil beam. This model is expected to be appropriate for a variety of processes which cause range variations. This includes variations of the primary proton energy due to uncertainties in the delivery system, relocation of skin folds, a varying thickness of fat layers (e.g. due to weight loss) or uncertainties in the conversion of Hounsfield units to stopping powers. Although the geometry of the model is stylized, we claim that it preserves reality in the relevant aspects.
Objective functions
Throughout the paper, we consider objective functions that penalize the deviation of the delivered dose and a prescribed dose in each voxel. For the probabilistic approach in section 4 we apply the quadratic objective function
whereas for the robust formulation we consider the absolute, linear deviation:
(2)
In equations (1) and (2), PAT denotes the set of all voxels in the patient,
is the prescribed dose for voxel i and
is a penalty factor that controls the trade-off between tumour coverage and sparing of healthy tissues. The vector w denotes the fluence map with beamlet weights, w j , as components. The dose D i to voxel i is determined according to D i = j ∈PB d j i w j where d j i is the dose contribution of beamlet j to voxel i for unit fluence and PB denotes the set of all beamlets. In equations (3) and (4), CTV, OAR and UT denote the sets of all tumour voxels, OAR voxels and unclassified tissue voxels, respectively, and satisfy CTV ∪ OAR ∪ UT = PAT.
Sensitivity of conventional treatment plans to range variations
In this section, we demonstrate that conventional treatment plans that are optimized without taking range uncertainties into account, may be very sensitive to range variations. We demonstrate this sensitivity in the case of optimizing the quadratic objective function (1). Using the piecewise linear objective (2) yields similar results. Figure 3 shows a treatment plan that was optimized without taking range uncertainties into account. Figure 3 (a) shows the resulting dose distribution when the nominal range is realized for each beamlet as assumed for the optimization. The dose distribution is homogeneous within the tumour 5 . cases, the dose distribution within the target becomes highly inhomogeneous. Furthermore, for the enlarged range (figure 3(b)), the dose delivered to the OAR is increased substantially, while for the shortened range, the edges of the tumour become underdosed. The deterioration of the dose distribution becomes obvious also in the dose-volume histogram in figure 2(a), which shows the DVHs of the dose distribution for the nominal range as well as for the 5 mm reduced/enlarged ranges.
Figures 3(d) and (e) show the dose distributions delivered by the individual beams at 45 • and 0 • , respectively. Note that the dose distribution delivered by the third beam at 315 • is a mirror image of the beam at 45 • due to the symmetry of the geometry. It is apparent in both figures that the distal edge of the Bragg peak is used to create a steep dose gradient at the transition of tumour and OAR, which clearly makes the dose delivered to the OAR sensitive to variations in the proton range. In addition, the dose distributions delivered by individual beams are highly inhomogeneous in beam direction. As a consequence, the dose delivered to the tumour does not add up to a homogeneous distribution if the dose distributions of the individual beams are displaced relative to each other.
A probabilistic approach for IMPT optimization
This section defines a probabilistic method to account for range uncertainties in IMPT optimization. We formulate an abstract model to describe range uncertainties (subsection 4.1) which is sufficient to formulate the optimization problem (subsection 4.2). In subsection 4.3 we specify the uncertainty model in detail.
The range uncertainty model I
For the geometric model introduced in section 2.1, the dose distribution of each beamlet j can be fully characterized by its range which we denote by ρ j . We consider the range to be a random variable, i.e. the 'true' range ρ j is assumed to be given by
whereρ j is the nominal range to be estimated from patient data. The parameter σ j characterizes the magnitude of the uncertainty and δ j is a random variable that determines by how much the 'true' range differs from the nominal range. Generally, the range shifts of two beamlets will not be independent. For example, the ranges of two beamlets that correspond to the same lateral position and the same beam direction (and only differ in the nominal range) will be affected in the same way. Consequently, the random variables δ j and δ k of two beamlets will in general be correlated. We assume that there exists a joint probability distribution P (δ) for the vector δ of range shifts with components δ j .
IMPT optimization incorporating range uncertainties
Since the objective value and the delivered dose to a voxel depend on the ranges of the beamlets, we must update the objective function (1) to take this uncertainty into account. The resulting objective can be written as
where the dose to voxel i is given by
and d j i (ρ j ) is the dose contribution of beamlet j to voxel i for unit fluence when the range of beamlet j is ρ j .
In order to account for the uncertainty in the optimization, we propose to minimize, with respect to the fluence map w, the expected value of E (where the expectation is taken over the ranges ρ):
where the integral represents a multi-dimensional integration over the ranges of all beamlets. Equation (8) can then be rewritten as
where
P j (δ j ) denotes the marginal probability distribution for the random variable δ j associated with the range of beamlet j , and P jk (δ j , δ k ) denotes the marginal probability distribution for the two random variables δ j and δ k , which may be correlated.
From (10) we see that the objective to be minimized can explicitly be written as a quadratic function of the beamlets weights w j . The minimization problem is unconstrained except for the non-negativity of w j and can be solved by standard gradient methods.
The range uncertainty model II
We now concretize the range uncertainty model. We assume that the random variables δ j are distributed according to a multivariate Gaussian distribution with mean values equal to zero and a covariance matrix C with elements C jk = δ j δ k :
The diagonal elements of C are equal to one since the magnitude of uncertainty is described by the parameters σ j . The non-diagonal elements of the covariance matrix will in general not be zero. Realistically, the correlation between the range shifts of two beamlets can hardly be determined experimentally. Therefore, we have to apply heuristic assumptions. In this paper, we assume the following correlation model:
• All beamlets which correspond to the same beam direction are shifted in the same way, whereas beamlets of different beam directions are statistically independent. Formally, this can be written as δ j δ k = 1 if the beamlets j and k belong to the same beam direction and δ j δ k = 0 if the beamlets j and k do not belong to the same beam direction.
In the limit C jk → 1 (j = k) the covariance matrix becomes singular and the inverse C −1 in equation (14) does not exist. However, the marginal distribution P jk (δ j , δ k ) needed to evaluate equation (11) 
is a Gaussian distribution with standard deviation one. We investigated other correlation models, too. For example, we assumed that the beamlets which do not correspond to the same lateral position in the same beam direction are statistically independent. Only beamlets at the same lateral position which only differ in depth, are assumed to be affected in the same way. Note that another correlation model only corresponds to another covariance matrix C, whereas the general formalism remains unchanged. Generally, the correlation model has some impact on the treatment plan, however, the resulting treatment plans turned out to be very similar on a qualitative level. Therefore, results are not discussed in more detail.
The variance of the dose
Based on the uncertainty model in subsections 4.1 and 4.3, we can calculate the variance of the dose delivered to each voxel:
The standard deviation (the square root of the variance) is a measure of the uncertainty of the dose due to range variations. The standard deviation can be used as a measure of the robustness of the treatment plan. A small value of the standard deviation of the dose in a voxel indicates that the dose delivered to that voxel is approximately constant, independent of the realized beamlet ranges. The variance of the dose is contained (and hence minimized) in the quadratic objective (8), which can be written as the sum of the variance and the quadratic difference of expected dose and prescribed dose (Unkelbach and Oelfke 2004) .
A robust formulation for handling range uncertainties
In this section, we introduce an alternative approach to handle range uncertainties in IMPT optimization. The approach is based on a linear formulation of the optimization problem and uses methods developed in the field of robust optimization in operations research. We assume that the range of the beamlet is random and may vary within some fixed interval. The robust formulation derived in this section can be interpreted as a worst case optimization. For each voxel, the maximum, absolute difference between the delivered and prescribed dose, which can occur for all possible range combinations, is minimized.
The uncertainty model
We assume that the range ρ j of each beamlet j may vary within some interval ρ j ∈ [ρ j − j ,ρ j + j ], whereρ j denotes the nominal range and j denotes the maximum possible deviation fromρ j . In practice, we discretize the possible ranges for each beamlet.
That is for each beamlet j , there exists a set of possible ranges ρ jr j , where r j ∈ R is an index of the realized range of beamlet j and R is the set of applicable range indices 6 . The dose delivered to a voxel depends on the vector ρ whose components are the ranges ρ j of the individual beamlets. For the results shown in section 6.2, we considered a maximum range deviation j = 5 mm for each beamlet and we allowed for 11 equally spaced range values.
In this section, we assume the same coupling of the beamlets as in section 4. That is the ranges of beamlets from different beam directions may vary independently, however, the range of beamlets in the same beam direction varies in the same way. Formally, this states that if two beamlets j and k belong to the same beam, their range indices r j and r k are the same. This allows us to define the uncertainty set U ρ of the uncertain optimization problem as the set of all range vectors ρ with components ρ jr j which satisfy the above condition:
where B denotes the set of all beams and PB b is the set of all beamlets which belong to beam b ∈ B. In this work, we will be optimizing w over the worst case that can be realized for the range vectors ρ ∈ U ρ . Note that changes in the assumption regarding correlation of the beamlet ranges can be modelled by modifying the uncertainty set U ρ .
Formulation of the robust optimization problem
We consider an objective function that minimizes the absolute difference of the dose and a prescribed dose in each voxel:
If we do not account for range uncertainties, we choose a particular range vector ρ from the uncertainty set, usually the nominal range for each beamlet. The optimization problem (not yet taking the uncertainty into account) can be written as a linear programming problem in the following form (Bertsimas and Tsitsiklis 1997) :
subject to
In (18)-(22), we rewrote the objective for the OAR in terms of constraints for later convenience.
In the next step, we account for range uncertainties by making the transition to the robust counterpart of the optimization problem (18)-(22). This is performed by requiring that constraints (19)-(21) hold for all possible range vectors in the uncertainty set U ρ . Formally, this can be written as
This formulation can be interpreted as optimizing over the worst case that can occur in the uncertainty set U ρ . For example, demanding that the constraint (26) holds for every ρ means that z i will be set to the maximum dose that is delivered to the OAR voxel i for all ρ in U ρ . For the unclassified normal tissue, we only penalize the integral dose delivered assuming the nominal range. Robustifying the constraints for the unclassified tissue is unnecessary since it has a negligible effect on the optimization result. And, it would substantially increase the number of constraints.
Since we discretized the possible ranges for each beam, (23)- (27) are still a linear program and could, in principle, be solved directly using a standard linear programming solver. However, the number of constraints increases exponentially with the number of beams. Assuming that we allow for R = 11 ranges for each of three beams, the set of constraints in (24) corresponds to 11 3 = 1331 linear constraints for each voxel. Consequently, the problem becomes intractable for a realistically-sized case. We therefore derive a formulation which is equivalent to (23)-(27), but requires fewer constraints. The derivation follows the idea presented by Chan et al (2006) in the context of robust optimization for handling respiratory motion in photon IMRT. The derivation can be found in the appendix.
It should be noted that each voxel is considered separately in the formulation (23)-(27). For each voxel we determine the worst beamlet ranges independently instead of determining the beamlet ranges which yield the worst overall dose distribution. For different voxels, the worst dose value will generally occur for a different combination of beamlet ranges. Realistically, the worst case which corresponds to the minimum of (23) can therefore not be realized. Although, it would be desirable to optimize the worst case which can really occur, there may not be a computationally tractable solution to that problem. And, the formulation suggested here yields adequate results.
Results
The probabilistic approach
In this section we demonstrate the capability of the probabilistic approach to reduce the sensitivity to range variations. We apply the optimization concept introduced in section 4 and assume a range uncertainty of σ j = 5 mm for all beamlets. Figure 5 4 . DVHs of the CTV and the OAR for the three treatment plans: (a) assuming that the range for all beamlets is reduced by 5 mm, (b) assuming that the range for all beamlets is enlarged by 5 mm.
dose distribution applying the optimized fluence map and assuming that the nominal ranges are realized for all beamlets. Figures 5(b) and (c) show the dose distributions delivered when the range of all beamlets is shortened/enlarged by 5 mm. A comparison to figures 3(b) and (c) shows that the sensitivity to range uncertainties is considerably reduced. The target coverage and homogeneity is substantially improved. Figures 5(d) and (e) show the qualitative difference of the probabilistic treatment plan compared to the conventional treatment plan in figure 3 . For the probabilistic optimization, the lateral fall-off of the Bragg peak is used to create the dose gradient between the tumour and the OAR. This avoids overdosage of the OAR for the case of enlarged ranges and underdosage of the tumour for reduced ranges. In addition, the dose distributions are more homogeneous in beam direction, a feature which is needed to ensure a homogeneous dose distribution in the tumour. The high dose regions are expanded into the unclassified tissue both, distal and proximal to the tumour. This is necessary in order to ensure tumour coverage for shorter and larger ranges, respectively. Since the probabilistically optimized treatment plan is optimal for an uncertain range, it cannot be optimal for the case in which the range is exactly known. Practically, this has to result in a deterioration of the dose distribution delivered for the nominal case. Since the lateral fall-off of the Bragg peak is more shallow than the distal fall-off, the dose to the OAR is increased for the probabilistic plan when one compares the dose distributions realized for the nominal range (figures 3(a) and 5(a)). This is the price one has to pay for the enhanced robustness against range uncertainties. The increase in dose to the OAR can also be seen in the DVHs for the nominal range in figure 2(b) . In addition, the dose burden of the unclassified tissue is increased because the high dose regions have to be expanded into the unclassified tissue. However, it is a major achievement of the proposed method, that the deterioration of the nominal dose distribution is moderate. The concept yields an adequate beam arrangement so that the expansion of the high dose region mainly affects the unclassified tissue and not the OAR.
Figures 3(f) and 5(f) show the standard deviation of the dose according to equation (15) for the conventional and the probabilistic treatment plan, respectively. As apparent in figure 3(f) , for the conventional treatment plan, the largest dose uncertainties (approximately 30% of the prescribed dose) occur in the transition region between the tumour and the OAR. In large regions of the tumour, the standard deviation is substantial, representing underdosing and overdosing of the tumour for different ranges. For the probabilistic approach ( figure 5(f) ), the dose uncertainty within the tumour is strongly reduced and is mainly restricted to the unclassified normal tissue. , 40, 60, 70, 80, 90,95, 100, 105, 110 and 120%.) 6.2. The robust approach Figure 6 shows a treatment plan which was optimized using the robust formulation. A maximum range deviation of j = 5 mm was assumed for each beamlet. As is apparent in figure 6((d)/(e)), this method yields qualitatively similar treatment plans compared to the probabilistic method. The lateral fall-off of the Bragg peak is used to shape the dose distribution at the transition between OAR and tumour. In addition, the dose distribution delivered by an individual beam is widely homogeneous in beam direction. These two 20, 40, 60, 70, 80, 90,95, 100, 105, 110 and 120%.) features make the dose delivered to the tumour and the OAR relatively insensitive to changes in the proton range. For the dose distributions that correspond to a shorter/larger range (figure 6((b)/(c))), the tumour coverage and the sparing of the OAR are much improved compared to the conventional treatment plan. This finding is confirmed by the DVHs in figures 2(b), 4(a) and (b). Particularly, the DVHs for the probabilistic and the robust treatment plan are very similar.
Figure 6(f) shows the maximum deviation of the delivered dose from the prescribed dose for the tumour voxels and OAR voxels (i.e. the values of the variables z i ). For the tumour, the largest deviations correspond to an underdosage close to the OAR, whereas the deviations in most other parts of the tumour are small. The maximum doses delivered to OAR voxels reach approximately 80% of the prescribed dose (note the different colour scales for tumour voxels and OAR voxels).
Discussion and conclusion
Conventional treatment plans optimized for IMPT can deteriorate substantially when the range of the proton beam does not match the range that was assumed during the optimization phase (section 3). This may not only lead to unexpectedly high doses to adjacent healthy structures, but also to hot/cold spots within the tumour. We proposed two methods to account for range uncertainties in IMPT optimization. The first method is referred to as the probabilistic approach (section 4). Following this approach, the expectation value of an objective function is optimized, which depends on a set of random variables (in this case, the ranges of the proton beams). The second approach is referred to as the robust formulation (section 5). We use methods developed in the field of robust linear programming to mitigate the effects of range variations.
Both approaches aim to minimize the deviation of the delivered dose from a prescribed dose. The major difference between both methods is as follows: the probabilistic approach considers all possible range variation scenarios. Every scenario is a term in the objective function, weighted with its probability to occur. The is represented by optimizing the expected value of the objective function. The robust approach does not perform a weighting of different scenarios, but instead minimizes the maximum deviation of delivered and prescribed dose, which can occur for all allowable ranges. Other than this fundamental difference, both approaches yield very similar results. In both cases, the resulting treatment plans are considerably less sensitive to range variations. The two solutions both avoid placing the distal edge of a Bragg peak directly in front of an adjacent OAR and, instead, the lateral fall-off is used to shape the dose distribution at the transition of the OAR and the tumour. Also, for both methods, the dose distributions delivered by individual beams are widely homogeneous in beam direction.
The latter aspect of robust treatment plans can be enforced by the 2.5D technique (Lomax 1999) . However, this method is more restrictive and does not work in all cases (including the patch-field geometry in section 8). Generally, it should be noted that treatment plans obtained by the probabilistic or robust method cannot be reproduced by a safety margin approach.
We demonstrated both approaches for an idealized geometry in order to clearly show the qualitative difference of the robustified treatment plans compared to conventional treatment plans. However, transferring these methods to realistic clinical data is not a conceptual problem as long as the dose distribution of an individual beamlet can be parameterized by its range. This applies for the commonly used pencil beam algorithms 7 . We do not expect considerably different results for the application to clinical data. Regarding the computational complexity, we assume that both approaches are feasible-although the computational effort certainly increases. In order to evaluate objective function (8) for the probabilistic approach, different methods could be applied. For the specific method introduced in equations (10)-(13) 20, 40, 60, 70, 80, 90,95, 100, 105, 110 and 120%.) a one-dimensional integration over the range shifts has to be solved for each pair of correlated beamlets 8 . However, the evaluation of this integral does not necessarily require many nodes. In addition, the integration over the range shifts can be decoupled from the iterative gradient based optimization process, that is, it has to be performed only once prior to the optimization, not in every optimization step.
Supplement: optimally abutting fields
In this section, we discuss another irradiation geometry, which we refer to as the patch-field geometry. We consider two beams with 90 • angular separation at 135 • and 225 • as indicated in figure 1. This represents a common beam geometry to irradiate horse shoe shaped tumours with passive scattering techniques (Bussiere and Adams 2003) . One beam (called the 'through field') irradiates the part of the tumour which is not blocked by the OAR with the prescribed dose. The second beam (called the patch field) irradiates the remaining part of the tumour which is not covered by the first field. This geometry is partly motivated by the consideration of range uncertainties, since it is an alternative to choosing only a single beam at 0 • which would stop directly in front of the OAR. On the other hand, this method is sensitive to range uncertainties itself. Hot or cold spots will arise at the patch line when the range of patch field is larger or shorter than expected.
Using intensity modulation, we are able to modulate the dose profiles of the individual fields in the overlap region in order to reduce the sensitivity of the tumour dose homogeneity to range variations. We apply the probabilistic concept presented in section 4 to optimize the dose distribution for the patch-field geometry. We assume a range uncertainty of σ j = 2.5 mm for all beamlets. Figure 7 illustrates the result. Figures 7(d) , (e) show the dose distributions of the individual fields. The dose profile in the overlap region resembles the shape of a spiral staircase, making the dose gradient as shallow as possible. Figures 7(a) -(c) show the dose distributions resulting for the nominal range (a), ranges reduced by 2.5 mm (b) and ranges enlarged by 2.5 mm (c). The dose delivered to the upper part of the tumour becomes relatively insensitive to range variations. However, near the OAR, hot or cold spots are still possible. The beam geometry does not allow for a solution which at the same time covers the tumour homogeneously, spares the OAR and in addition avoids a steep dose gradient. Figure 7(f) shows the standard deviation of the dose and confirms that finding.
We now replace the problem (23) where d jr i = d j i ρ jr j is the dose contribution of the beamlet j to voxel i if the range index of that beamlet is r, i.e. the actual range is ρ jr . At first, the problem (A.2)-(A.6) seems to be different from the formulation (23)-(27). In (A.2)-(A.6), we allow the dose in a voxel to be a superposition of dose contributions from different ranges, which is not the case in (23)-(27). However, (23)- (27) and (A.2)-(A.6) are in fact equivalent which is shown below.
In order to satisfy the constraints in (A.3)-(A.5) for all P in the uncertainty set, we only have to consider the worst case for each voxel. We focus on the first constraint (A.3), which penalizes underdosing the tumour. In order to satisfy this constraint for all P , it has to be satisfied for the specific P which yields the minimal dose in that voxel. We rewrite (A.3) as
where for any given fluence map w,D i (w) is defined as the minimum of the delivered dose to voxel i with respect to all P in the uncertainty set U P : Hence, for any given w and any voxel i,D i (w) is the minimum of a linear programming problem. The 'optimal' P (in fact the worst case P ) corresponds to a corner point of the feasible region (that is a corner point of the uncertainty set U P ). The corner points of the feasible region correspond to a P , where for each beam b, P br is equal to 1 for a particular range r and 0 for all other ranges. As a consequence, the formulations (23)- (27) and (A.2)-(A.6) are equivalent. For a general introduction to linear optimization see for example Bertsimas and Tsitsiklis (1997) .
To proceed, we apply the theory of duality in linear programming and formulate the dual problem of (A.8)-(A.11), which is given by 
